TREATMENT OF HER2+ CANCER USING AN AGENT THAT MODULATES THE ACTIVITY OF A MIRNA

Approximately 25% of primary human breast cancers are due to deregulated ErbB2/HER2 expression. Therapies targeting HER2 have improved patient survival, but de novo and acquired resistance remain a challenge, with only 25% of treated patients responding to current therapies. The researchers identified several miRNAs in the miR-200 family that are upregulated in HER2+ breast cancer cells and tumor samples and whose high expression levels are associated with worse prognosis in HER2+ breast cancer patients. They designed, optimized and validated a novel biotherapeutic ASO molecule for the inactivation of miRNA-429 for the treatment of cancers with HER2 abnormalities, including HER2+ breast, gastric and ovarian cancers.

Applications:

• Novel anti-miRNA biotherapy based on an ASO strategy
• HER2+ cancers, including breast, gastric and ovarian cancers

Competitive advantages:

• Therapeutic efficacy on HER2+ breast, gastric and ovarian cancer cells, including tumors that are resistant to the current therapeutic arsenal.

Keywords: HER2+ cancers, Breast, gastric, ovarian cancers, Targeted Biotherapies, MiRNA, Personalized medicine, Antisense oligonucleotides